Skip to Content

Infliximab May Impede Serologic Response to SARS-CoV-2

TUESDAY, March 23, 2021 -- For patients with inflammatory bowel disease (IBD), infliximab is associated with attenuated serological responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published online March 22 in Gut.

Nicholas A. Kennedy, M.B.B.S., from the Royal Devon and Exeter NHS Foundation Trust in the United Kingdom, and colleagues compared antibody responses in patients with IBD treated with infliximab compared to a reference cohort treated with vedolizumab. Between Sept. 22 and Dec. 23, 2020, 6,935 patients were recruited from 92 U.K. hospitals.

The researchers found that between the groups, the rates of symptomatic and proven SARS-CoV-2 infection were similar. Compared with vedolizumab-treated patients, infliximab-treated patients had lower seroprevalence (3.4 versus 6.0 percent). Infliximab and immunomodulatory use were independently associated with lower seropositivity in multivariable analyses (odds ratios, 0.66 and 0.70, respectively). Seroconversion occurred in fewer infliximab-treated versus vedolizumab-treated patients among those with confirmed SARS-CoV-2 infection (48 versus 83 percent), and the magnitude of anti-SARS-CoV-2 reactivity was lower (median, 0.8 versus 37.0 cutoff index).

"Impaired serological responses to SARS-CoV-2 infection might have important implications for global public health policy and millions of anti-tumor necrosis factor treated patients," the authors write. "Serological testing and virus surveillance should be considered to detect suboptimal vaccine responses, persistent infection and viral evolution to inform public health policy."

Several authors disclosed financial ties to the biopharmaceutical industry; F. Hoffmann-La Roche, Biogen GmbH, and Celltrion Healthcare funded the study.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Read this next

Response to One COVID-19 Vaccine Dose Strong in Previously Infected

FRIDAY, April 16, 2021 -- For persons with a history of previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the neutralizing antibody titer is...

Booster Shots a Likely Reality for COVID-19-Vaccinated Americans

FRIDAY, April 16, 2021 -- Vaccinated Americans will probably need booster shots to guard against emerging coronavirus variants in the future, a White House adviser and Pfizer said...

Hemorrhagic Stroke + COVID-19 Doubles Risk for In-Hospital Mortality

FRIDAY, April 16, 2021 -- COVID-19 ups the risk for death with hemorrhagic stroke by more than twofold, according to a study published online April 14 in PLOS ONE. Vijay M....

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.